Key result
Patients with pathogenic SCN4A variants exhibited a 2.5% greater intramuscular fat fraction in the calves and 14-27% less muscle contractility compared to healthy controls.
Why the study?
Chronic symptoms with permanent weakness are not considered typical of skeletal muscle sodium channel disorders, but muscle fat replacement represents irreversible damage that impacts muscle strength.
Cross-Sectional (n=62)
Single-blind
No
Patients with skeletal muscle sodium channel disorders exhibit greater muscle fat replacement and reduced muscle contractility compared to healthy controls, though absolute strength is preserved due to muscle hypertrophy.
Answers are grounded in this paper and cite their sources.
SCN4A variants associate with greater fat fraction and reduced contractility despite preserved strength; leaves open progression to permanent weakness.
Skeletal muscle sodium channel disorders give rise to episodic symptoms such as myotonia and/or periodic paralysis. Chronic symptoms with permanent weakness are not considered characteristic of the phenotypes. Muscle fat replacement represents irreversible damage that inevitably will impact on muscle strength. This study investigates muscle fat replacement and contractility in patients with pathogenic SCN4A variants compared to healthy controls. T1-weighted and 2-point Dixon MRI of the legs were conducted to assess fat replacement. Stationary dynamometry was used to assess muscle strength. Contractility was determined by maximal muscle contraction divided by cross-sectional muscle area. The average cross-sectional intramuscular fat fraction was greater in patients compared with controls by 2.5% in the calves (95% CI 0.74-4.29%, p = 0.007) and by 2.0% in the thighs (95% CI 0.75-3.2%, p = 0.003). Muscle contractility was less in patients vs. controls by 14-27% (p < 0.05). Despite greater fat fraction and less contractility, absolute strength was not significantly less. This study quantitatively documents greater fat fraction and additionally describes difference in muscle contractility in a large cohort of patients with skeletal muscle sodium channel disorders. The clinical impact of these abnormal findings is likely limited as muscle hypertrophy in the patients served to preserve absolute muscle strength. Subgroup analysis indicated significant difference in phenotype by genotype, however these findings lack statistical significance and serve as inspiration for future researchers to probe into the geno- phenotype relationship in these disorders.Trial registration: The study was registered at http://clinicaltrials.gov (identifier: NCT04808388).
No takes yet. Share an insight, caveat, or question.
Pedersen et al. (2023) conducted a cross-sectional in Skeletal muscle sodium channel disorders (n=62). Pathogenic SCN4A variants vs. Healthy controls was evaluated on Average cross-sectional intramuscular fat fraction in the calves (MD 2.5%, 95% CI 0.74-4.29, p=0.007). Patients with pathogenic SCN4A variants exhibited a 2.5% greater intramuscular fat fraction in the calves and 14-27% less muscle contractility compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: